Skip to content

Avalus European Registry - an Observational Study to Evaluate Safety and Efficacy in a Real World Population

Avalus European Registry - an Observational Study to Evaluate Safety and Efficacy in a Real World Population

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05572710
Acronym
Avalus
Enrollment
1000
Registered
2022-10-10
Start date
2020-06-10
Completion date
2025-12-31
Last updated
2024-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Valve Insufficiency, Aortic Valve Stenosis

Brief summary

This is a prospective, observational, single-arm, multi-center registry of patients undergoing bioprosthetic aortic valve replacement with the Avalus valve. This prospective registry aims to examine the outcome and performance of surgical aortic valve replacement with the Avalus pericardial bioprosthesis.

Detailed description

The study is a prospective, observational, single-arm, multi-center registry. The patients must undergoing bioprosthetic aortic valve replacement with the Avalus valve. This prospective registry aims to examine the outcome and performance of surgical aortic valve replacement with the Avalus pericardial bioprosthesis. The goal of this project is to evaluate the real world results of aortic valve replacement with the Avalus valve. This will result in clinical and hemodynamic knowledge of this particular valve. The investigators are aiming for 1000 patient inclusions distributed over 40 sites across Europe and potentially also involving Canada. Intentionally, we kept the inclusion criteria as wide as possible in order to obtain a real-world experience with and performance of the bioprosthesis. Patients younger than 18 years and salvage procedures are the only exclusion criteria from the registry. Outcome is evaluated in accordance with the VARC-2 criteria up to 1-year postoperatively.

Interventions

None listed

Sponsors

Universitaire Ziekenhuizen KU Leuven
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Clinical indication for replacement of the native or prosthetic aortic valve with a bioprosthesis * Age \>= 18 years * Patient has been adequately informed of risks and requirements of the registry (which are actually limited since the prosthesis is in full commercial use and only data registration is performed) and is able to provide informed consent for participation in the clinical registry.

Exclusion criteria

* Patient requires salvage surgery (according to EuroSCORE II definitions: patients requiring cardiopulmonary resuscitation (external cardiac massage) en route to the operating theatre or prior to induction of anaesthesia. This does not include cardiopulmonary resuscitation following induction of anaesthesia) * Not been able to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Composite of all-cause mortality and disabling stroke1 yearComposite of all-cause mortality and disabling stroke

Secondary

MeasureTime frameDescription
VARC-21 yearMortality, stroke, bleeding complications, major vascular complications, new pacemaker implantation, prostethic valve function, composit endpoints

Countries

Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Spain

Contacts

Primary ContactBart Meuris
bart.meuris@uzleuven.be+32 16 344260
Backup ContactTom Verbelen
tom.verbelen@uzleuven.be+32 16 344260

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026